Key result
Transcatheter valve replacement has emerged as an innovative treatment for degenerative aortic stenosis across risk profiles, though careful patient selection remains essential for optimal outcomes.
Why the study?
With percutaneous valve replacement increasingly offered to moderate- and low-risk patients with aortic stenosis, defining appropriate patient selection is essential to achieve optimal outcomes.
Transcatheter valve replacement has revolutionized the treatment of degenerative aortic stenosis, expanding treatment options from high-risk to moderate and low-risk patients.
Highlights importance of careful TAVR selection in aortic stenosis; leaves open precise criteria to optimize outcomes across risk profiles.
Degenerative aortic stenosis is the most common valvular disease worldwide; however, its physiopathology remains poorly understood. Although, developments in prevention of this disease have remained relatively stagnant, the last decade has brought about innovative treatment options incorporating different percutaneous and surgical approaches. These advances have allowed physicians to offer relief to high-risk patients, previously deemed nonsurgical. Increasingly, there is a shift toward offering percutaneous valve replacement to moderate and low-risk patients with aortic stenosis. Enthusiasm for a new treatment option must always be tempered by caution; as defining appropriate patient selection is essential to achieve optimal outcomes.
No takes yet. Share an insight, caveat, or question.
Huu et al. (2020) conducted a review in Degenerative aortic stenosis. Transcatheter Valve Replacement was evaluated. Transcatheter valve replacement has emerged as an innovative treatment for degenerative aortic stenosis across risk profiles, though careful patient selection remains essential for optimal outcomes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: